Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Guaifenesin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B known ✓ | P29275 | 6/20 | 0.52 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.52 |
| ▸ | PDE4A known ✓ | P27815 | 4/20 | 0.52 |
| ▸ | PDE4B known ✓ | Q07343 | 4/20 | 0.52 |
| ▸ | PDE4C known ✓ | Q08493 | 4/20 | 0.52 |
| ▸ | PDE4D known ✓ | Q08499 | 4/20 | 0.52 |
| ▸ | ADORA2A known ✓ | P29274 | 3/20 | 0.52 |
| ▸ | ADORA1 known ✓ | P30542 | 2/20 | 0.52 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guaifenesin SCHEMBL30669734 | 1.00 | LMNA (0.55) | LMNACYP1A2AGTR1ATAD2ADORA2B | |
| Guaifenesin SCHEMBL8714199 | 0.96 | LMNA (0.58) | LMNACYP1A2AGTR1ATAD2ADORA2B | |
| Guaifenesin SCHEMBL2527795 | 0.89 | CYP1A2 (0.43) | LMNACYP1A2AGTR1ATAD2ADORA2B | |
| Guaifenesin SCHEMBL2524333 | 0.88 | ADORA2B (0.43) | LMNACYP1A2AGTR1ATAD2ADORA2B | |
| Theophylline Anhydrous SCHEMBL10494896 | 0.77 | ATAD2 (0.74) | LMNACYP1A2ATAD2ADORA2BADORA3 | |
| Theophylline Anhydrous SCHEMBL437957 | 0.77 | ATAD2 (0.84) | LMNACYP1A2ATAD2ADORA2BADORA3 | |
| Theophylline Anhydrous SCHEMBL11422742 | 0.76 | ATAD2 (0.81) | LMNACYP1A2ATAD2ADORA2BADORA3 | |
| Theophylline Anhydrous SCHEMBL28294581 | 0.74 | ATAD2 (0.84) | LMNACYP1A2ATAD2ADORA2BADORA3 | |
| Guaifenesin SCHEMBL160234 | 0.74 | CYP1A2 (1.00) | LMNACYP1A2AGTR1CYP2C19MAPT | |
| Guaifenesin SCHEMBL4321 | 0.74 | CYP1A2 (1.00) | LMNACYP1A2AGTR1CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2729136-A1 | DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION | Biocopea Limited (GB) | 2014-05-14 | — | — | EP | claimed |
| EP-2608847-A1 | THEOBROMINE IN COMBINATION WITH AN EXPECTORANT OR A MUCOLYTIC FOR USE IN THERAPY | Biocopea Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| CN-103189108-A | Theobromine in combination with an expectorant or a mucolytic for use in therapy | BIOCOPEA LTD | 2013-07-03 | — | — | CN | claimed |
| WO-2013004999-A1 | DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION | BIOCOPEA LIMITED (GB) | 2013-01-10 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2012025761-A1 | THEOBROMINE IN COMBINATION WITH AN EXPECTORANT OR A MUCOLYTIC FOR USE IN THERAPY | BIOCOPEA LIMITED (GB) | 2012-03-01 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009143297-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | ADORA2B 1547/4885ADORA3 1316/4885PDE4A 381/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | ADORA2B 1547/4885ADORA3 1316/4885PDE4A 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.